JON HALBERT - 27 Feb 2025 Form 4 Insider Report for Caris Life Sciences, Inc. (CAI)

Role
Director
Signature
/s/ J. Russel Denton, Attorney-in-Fact
Issuer symbol
CAI
Transactions as of
27 Feb 2025
Net transactions value
$0
Form type
4
Filing time
23 Jun 2025, 18:38:00 UTC
Next filing
17 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
HALBERT JON Director C/O CARIS LIFE SCIENCES, INC., 750 W. JOHN CARPENTER FREEWAY, SUITE 800, IRVING /s/ J. Russel Denton, Attorney-in-Fact 23 Jun 2025 0001189394

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CAI Common Stock Award $0 +16,129 +16% $0.000000 116,129 27 Feb 2025 Direct F1
transaction CAI Common Stock Conversion of derivative security $0 +1,250,000 $0.000000 1,250,000 20 Jun 2025 By Ke'Ohana Ventures, LLC F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CAI Series A Preferred Stock Conversion of derivative security -5,000,000 -100% 0 20 Jun 2025 Common Stock 1,250,000 $0.000000 By Ke'Ohana Ventures, LLC F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents an award of restricted stock units which vest in accordance with the applicable grant agreement. These restricted stock units were previously reported on the Reporting Person's Form 3. All the securities reported in this Form 4 reflect a one-for-four reverse stock split effected as of June 1, 2025.
F2 Each share of preferred stock automatically converted into 0.25 shares of Common Stock of the Issuer upon the closing of the initial public offering of the Issuer's Common Stock.
F3 The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein.